While our study showed that anastrozole effectively optimizes growth in patients with CAH via inhibition of estrogen-mediated bone age advancement, it does not target other androgen or ACTH-mediated side effects, such as increased virilization and testicular adrenal rests. Here, POMC is linked to congenital adrenal hyperplasia.